Michael Rees, MD
Internal Medicine · Raleigh, NCNPI 1144270737
Payments from drug & device makers
Across 412 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Amgen$660
- Lilly USA, LLC$438
- AstraZeneca$358
- Boehringer Ingelheim$345
- AbbVie$316
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,248100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 121 | $1,863 |
| Amgen(2 entities) | 55 | $660 |
| Lilly USA, LLC | 32 | $438 |
| AstraZeneca | 26 | $358 |
| Boehringer Ingelheim | 22 | $345 |
| AbbVie(2 entities) | 20 | $316 |
| Abbott | 7 | $182 |
| Sanofi-aventis U.S. LLC | 12 | $173 |
| Merck | 11 | $147 |
| Johnson & Johnson | 10 | $146 |
| Pfizer | 9 | $145 |
| Amarin Pharma, Inc. | 10 | $142 |
| Bayer | 7 | $141 |
| Kowa Pharmaceuticals America, Inc. | 10 | $140 |
| Novartis | 9 | $136 |
| Bausch Health US, LLC | 6 | $124 |
| Astellas Pharma US Inc | 5 | $110 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $102 |
| GSK | 5 | $85 |
| Medtronic | 4 | $73 |
| IBSA Pharma Inc. | 2 | $68 |
| Esperion Therapeutics, Inc. | 4 | $60 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Genentech USA, Inc. | 2 | $34 |
| Dexcom, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Seqirus USA Inc | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$6,256 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 119 | $121,110 |
| EliquisApixaban | 122 | $102,625 |
| TrulicityDulaglutide | 94 | $97,975 |
| MounjaroTirzepatide | 79 | $83,738 |
| RybelsusSemaglutide | 50 | $74,459 |
| OzempicSemaglutide | 63 | $58,068 |
| Repatha SureclickEvolocumab | 52 | $54,744 |
| XareltoRivaroxaban | 17 | $25,147 |
| Bydureon BciseExenatide Microspheres | 14 | $15,435 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $11,532 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $7,934 |
| SynjardyEmpagliflozin/Metformin Hcl | 12 | $7,217 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $6,375 |
| NexletolBempedoic Acid | 12 | $6,220 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $4,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $438 | $181,714173 claims |
| Novo NordiskRybelsus, Ozempic | $1,863 | $132,527113 claims |
| Boehringer IngelheimJardiance, Synjardy | $345 | $128,327131 claims |
| PfizerEliquis, Paxlovid | $145 | $104,055138 claims |
| Johnson & JohnsonXarelto | $146 | $25,14717 claims |
| MerckJanumet | $147 | $7,93413 claims |
| Esperion Therapeutics, Inc.Nexletol | $60 | $6,22012 claims |
| AbbVieSynthroid | $316 | $3,29536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Raleigh
- John RubinoRaleigh$13M
- Wayne HarperRaleigh$6.7M
- Bhakti PaulRaleigh$536K
- Clifford CurtisRaleigh$376K
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.